Human Coronavirus Respiratory Infections

Human Respiratory Viral Infections

Volumn , Issue , 2014, Pages 547-558

  Cecere, Thomas Edward ^a   Todd, Stephanie Michelle ^a   Richmond, Owen Benjamin ^a  

^a VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85091251010     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b16778-27     Document Type: Chapter

References (92)

1. Wevers BA, van der Hoek L. Recently discovered human coronaviruses. Clinics in Laboratory Medicine. 2009; 29(4): 715-24.
2. Vabret A, Dina J, Brison E, Brouard J, Freymuth F. Human coronaviruses. Pathological Biology (Paris). 2009; 57(2): 149-60.
3. Perlman S, Netland J. Coronaviruses post-SARS: Update on replication and pathogenesis. Nature Reviews Microbiology. 2009; 7(6): 439-50.
4. van der Hoek L, Pyrc K, Jebbink MF, Vermeulen-Oost W, Berkhout RJ, Wolthers KC et al. Identification of a new human coronavirus. Nature Medicine. 2004; 10(4): 368-73.
5. Masters PS. The molecular biology of coronaviruses. Advances in Virus Research. 2006; 66: 193-292.
6. Lissenberg A, Vrolijk MM, van Vliet AL, Langereis MA, de Groot-Mijnes JD, Rottier PJ et al. Luxury at a cost? Recombinant mouse hepatitis viruses expressing the accessory hemagglutinin esterase protein display reduced fitness in vitro. Journal of Virology. 2005; 79(24): 15054-63.
7. Weiss SR, Leibowitz JL. Coronavirus pathogenesis. Advances in Virus Research. 2011; 81: 85-164.
8. DeDiego ML, Nieto-Torres JL, Jimenez-Guardeno JM, Regla-Nava JA, Alvarez E, Oliveros JC et al. Severe acute respiratory syndrome coronavirus envelope protein regulates cell stress response and apoptosis. PLoS Pathogens. 2011; 7(10): e1002315.
9. DeDiego ML, Alvarez E, Almazan F, Rejas MT, Lamirande E, Roberts A et al. A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo. Journal of Virology. 2007; 81(4): 1701-13.
10. Ortego J, Ceriani JE, Patino C, Plana J, Enjuanes L. Absence of E protein arrests transmissible gastroenteritis coronavirus maturation in the secretory pathway. Virology. 2007; 368(2): 296-308.
11. Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH et al. Bats are natural reservoirs of SARS-like coronaviruses. Science. 2005; 310(5748): 676-9.
12. Al-Tawfiq JA. Middle East Respiratory Syndrome-coronavirus infection: An overview. Journal of Infection and Public Health. 2013; 6(5): 319-22.
13. van der Hoek L. Human coronaviruses: What do they cause? Antiviral Therapy. 2007; 12(4 Pt B): 651-8.
14. Abdul-Rasool S, Fielding BC. Understanding Human Coronavirus HCoV-NL63. The Open Virology Journal. 2010; 4: 76-84.
15. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. The New England Journal of Medicine. 2012; 367(19): 1814-20.
16. Li W, Sui J, Huang IC, Kuhn JH, Radoshitzky SR, Marasco WA et al. The S proteins of human coronavirus NL63 and severe acute respiratory syndrome coronavirus bind overlapping regions of ACE2. Virology. 2007; 367(2): 367-74.
17. Hofmann H, Pyrc K, van der Hoek L, Geier M, Berkhout B, Pohlmann S. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102(22): 7988-93.
18. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nature Medicine. 2005; 11(8): 875-9.
19. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005; 436(7047): 112-6.
20. Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, Cheung CL et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science. 2003; 302(5643): 276-8.
21. Wang LF, Eaton BT. Bats, civets and the emergence of SARS. Current topics in microbiology and immunology. 2007; 315: 325-44.
22. Poon LL, Guan Y, Nicholls JM, Yuen KY, Peiris JS. The aetiology, origins, and diagnosis of severe acute respiratory syndrome. The Lancet Infectious Diseases. 2004; 4(11): 663-71.
23. de Groot RJ, Baker SC, Baric RS, Brown CS, Drosten C, Enjuanes L et al. Middle East respiratory syndrome coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group. Journal of Virology. 2013; 87(14): 7790-2.
24. van Boheemen S, de Graaf M, Lauber C, Bestebroer TM, Raj VS, Zaki AM et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. mBio. 2012; 3(6).
25. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: A descriptive study. The Lancet Infectious Diseases. 2013; 13(9): 752-61.
26. Update: Severe respiratory illness associated with a novel coronavirus-Worldwide, 2012-2013. MMWR Morbidity and Mortality Weekly Report. 2013; 62(10): 194-5.
27. Evidence of person-to-person transmission within a family cluster of novel coronavirus infections, United Kingdom, February 2013. Euro Surveillance: Bulletin europeen sur les Maladies Transmissibles = European Communicable Disease Bulletin. 2013; 18(11): 20427.
28. Garbino J, Crespo S, Aubert JD, Rochat T, Ninet B, Deffernez C et al. A prospective hospital-based study of the clinical impact of non-severe acute respiratory syndrome (non-SARS)-related human coronavirus infection. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2006; 43(8): 1009-15.
29. Jartti T, Jartti L, Ruuskanen O, Soderlund-Venermo M. New respiratory viral infections. Current Opinion in Pulmonary Medicine. 2012; 18(3): 271-8.
30. Zhao Z, Zhang F, Xu M, Huang K, Zhong W, Cai W et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. Journal of Medical Microbiology. 2003; 52(Pt 8): 715-20.
31. Breiman RF, Evans MR, Preiser W, Maguire J, Schnur A, Li A et al. Role of China in the quest to define and control severe acute respiratory syndrome. Emerging Infectious Diseases. 2003; 9(9): 1037-41.
32. Rosling L, Rosling M. Pneumonia causes panic in Guangdong province. BMJ. 2003; 326(7386): 416.
33. Memish ZA, Zumla AI, Al-Hakeem RF, Al-Rabeeah AA, Stephens GM. Family cluster of Middle East respiratory syndrome coronavirus infections. The New England Journal of Medicine. 2013; 368(26): 2487-94.
34. Buchholz U, Muller M, Nitsche A, Sanewski A, Wevering N, Bauer-Balci T et al. Contact investigation of a case of human novel coronavirus infection treated in a German hospital, October-November 2012. Euro Surveillance: Bulletin Europeen sur les Maladies Transmissibles = European Communicable Disease Bulletin. 2013; 18(8).
35. Guery B, Poissy J, el Mansouf L, Sejourne C, Ettahar N, Lemaire X et al. Clinical features and viral diagnosis of two cases of infection with Middle East Respiratory Syndrome coronavirus: A report of nosocomial transmission. The Lancet. 2013; 381(9885): 2265-72.
36. Mailles A, Blanckaert K, Chaud P, van der Werf S, Lina B, Caro V et al. First cases of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infections in France, investigations and implications for the prevention of human-to-human transmission, France, May 2013. Euro Surveillance: Bulletin Europeen sur les Maladies Transmissibles = European Communicable Disease Bulletin. 2013; 18(24).
37. Bermingham A, Chand MA, Brown CS, Aarons E, Tong C, Langrish C et al. Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. Euro Surveillance: Bulletin Europeen sur les Maladies Transmissibles = European Communicable Disease Bulletin. 2012; 17(40): 20290.
38. Albarrak AM, Stephens GM, Hewson R, Memish ZA. Recovery from severe novel coronavirus infection. Saudi Medical Journal. 2012; 33(12): 1265-9.
39. Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeah AA, Cummings DA et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. The New England Journal of Medicine. 2013; 369(5): 407-16.
40. Cecere TE, Todd SM, Leroith T. Regulatory T cells in arterivirus and coronavirus infections: Do they protect against disease or enhance it? Viruses. 2012; 4(5): 833-46.
41. Zhou H, Perlman S. Mouse hepatitis virus does not induce Beta interferon synthesis and does not inhibit its induction by double-stranded RNA. Journal of Virology. 2007; 81(2): 568-74.
42. Versteeg GA, Bredenbeek PJ, van den Worm SH, Spaan WJ. Group 2 coronaviruses prevent immediate early interferon induction by protection of viral RNA from host cell recognition. Virology. 2007; 361(1): 18-26.
43. He R, Leeson A, Andonov A, Li Y, Bastien N, Cao J et al. Activation of AP-1 signal transduction pathway by SARS coronavirus nucleocapsid protein. Biochemical and Biophysical Research Communications. 2003; 311(4): 870-6.
44. Kopecky-Bromberg SA, Martinez-Sobrido L, Frieman M, Baric RA, Palese P. Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. Journal of Virology. 2007; 81(2): 548-57.
45. Suresh MR, Bhatnagar PK, Das D. Molecular targets for diagnostics and therapeutics of severe acute respiratory syndrome (SARS-CoV). Journal of Pharmacy and Pharmaceutical Sciences. 2008; 11(2): 1s-13s.
46. Fouchier RA, Kuiken T, Schutten M, van Amerongen G, van Doornum GJ, van den Hoogen BG et al. Aetiology: Koch’s postulates fulfilled for SARS virus. Nature. 2003; 423(6937): 240.
47. Osterhaus AD, Fouchier RA, Kuiken T. The aetiology of SARS: Koch’s postulates fulfilled. Philosophical Transactions of the Royal Society of London Series B, Biological Sciences. 2004; 359(1447): 1081-2.
48. Chan KH, Poon LL, Cheng VC, Guan Y, Hung IF, Kong J et al. Detection of SARS coronavirus in patients with suspected SARS. Emerging Infectious Diseases. 2004; 10(2): 294-9.
49. Hung EC, Chim SS, Chan PK, Tong YK, Ng EK, Chiu RW et al. Detection of SARS coronavirus RNA in the cerebrospinal fluid of a patient with severe acute respiratory syndrome. Clinical Chemistry. 2003; 49(12): 2108-9.
50. Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: A prospective study. The Lancet. 2003; 361(9371): 1767-72.
51. Sunwoo HH, Palaniyappan A, Ganguly A, Bhatnagar PK, Das D, El-Kadi AO et al. Quantitative and sensitive detection of the SARS-CoV spike protein using bispecific monoclonal antibody-based enzyme-linked immunoassay. Journal of Virological Methods. 2013; 187(1): 72-8.
52. Wu HS, Chiu SC, Tseng TC, Lin SF, Lin JH, Hsu YH et al. Serologic and molecular biologic methods for SARS-associated coronavirus infection, Taiwan. Emerging Infectious Diseases. 2004; 10(2): 304-10.
53. Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. The New England Journal of Medicine. 2003; 348(20): 1967-76.
54. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S et al. A novel coronavirus associated with severe acute respiratory syndrome. The New England Journal of Medicine. 2003; 348(20): 1953-66.
55. Poon LL, Wong BW, Chan KH, Leung CS, Yuen KY, Guan Y et al. A one step quantitative RT-PCR for detection of SARS coronavirus with an internal control for PCR inhibitors. Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology. 2004; 30(3): 214-7.
56. Adachi D, Johnson G, Draker R, Ayers M, Mazzulli T, Talbot PJ et al. Comprehensive detection and identification of human coronaviruses, including the SARS-associated coronavirus, with a single RT-PCR assay. Journal of Virological Methods. 2004; 122(1): 29-36.
57. Chan PK, To WK, Ng KC, Lam RK, Ng TK, Chan RC et al. Laboratory diagnosis of SARS. Emerging Infectious Diseases. 2004; 10(5): 825-31.
58. Leung DT, Tam FC, Ma CH, Chan PK, Cheung JL, Niu H et al. Antibody response of patients with severe acute respiratory syndrome (SARS) targets the viral nucleocapsid. The Journal of Infectious Diseases. 2004; 190(2): 379-86.
59. Che XY, Qiu LW, Pan YX, Wen K, Hao W, Zhang LY et al. Sensitive and specific monoclonal antibody-based capture enzyme immunoassay for detection of nucleocapsid antigen in sera from patients with severe acute respiratory syndrome. Journal of Clinical Microbiology. 2004; 42(6): 2629-35.
60. Corman VM, Eckerle I, Bleicker T, Zaki A, Landt O, Eschbach-Bludau M et al. Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Euro Surveillance: Bulletin Europeen sur les Maladies Transmissibles = European Communicable Disease Bulletin. 2012; 17(39).
61. Corman VM, Muller MA, Costabel U, Timm J, Binger T, Meyer B et al. Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. Euro Surveillance: Bulletin Europeen sur les Maladies Transmissibles = European Communicable Disease Bulletin. 2012; 17(49).
62. Coughlin MM, Prabhakar BS. Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential. Reviews in Medical Virology. 2012; 22(1): 2-17.
63. Peiris JSMG, Y.; Yuen, K.Y. Severe acute respiratory syndrome. Nature Medicine. 2004; 10: S88-S97.
64. Golda A, Pyrc K. Recent antiviral strategies against human coronavirus-related respiratory illnesses. Current Opinion in Pulmonary Medicine. 2008; 14(3): 248-53.
65. Struck AW, Axmann M, Pfefferle S, Drosten C, Meyer B. A hexapeptide of the receptor-binding domain of SARS corona virus spike protein blocks viral entry into host cells via the human receptor ACE2. Antiviral Research. 2012; 94(3): 288-96.
66. Chuck CP, Chen C, Ke Z, Chi-Cheong Wan D, Chow HF, Wong KB. Design, synthesis and crystallographic analysis of nitrile-based broad-spectrum peptidomimetic inhibitors for coronavirus 3C-like proteases. European Journal of Medicinal Chemistry. 2013; 59: 1-6.
67. Chuck CP, Chow HF, Wan DC, Wong KB. Profiling of substrate specificities of 3C-like proteases from group 1, 2a, 2b, and 3 coronaviruses. PloS One. 2011; 6(11): e27228.
68. Kim Y, Lovell S, Tiew KC, Mandadapu SR, Alliston KR, Battaile KP et al. Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses. Journal of Virology. 2012; 86(21): 11754-62.
69. Park JY, Kim JH, Kim YM, Jeong HJ, Kim DW, Park KH et al. Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases. Bioorganic and Medicinal Chemistry. 2012; 20(19): 5928-35.
70. Keum YS, Jeong YJ. Development of chemical inhibitors of the SARS coronavirus: Viral helicase as a potential target. Biochemical Pharmacology. 2012; 84(10): 1351-8.
71. Yu MS, Lee J, Lee JM, Kim Y, Chin YW, Jee JG et al. Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13. Bioorganic and Medicinal Chemistry Letters. 2012; 22(12): 4049-54.
72. Lee C, Lee JM, Lee NR, Jin BS, Jang KJ, Kim DE et al. Aryl diketoacids (ADK) selectively inhibit duplex DNA-unwinding activity of SARS coronavirus NTPase/helicase. Bioorganic and Medicinal Chemistry Letters. 2009; 19(6): 1636-8.
73. Adedeji AO, Singh K, Calcaterra NE, DeDiego ML, Enjuanes L, Weiss S et al. Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicase. Antimicrobial Agents and Chemotherapy. 2012; 56(9): 4718-28.
74. Stockman LJ, Bellamy R, Garner, P. SARS: Systematic review of treatment effects. PLoS Med. 2006; 3: e343.
75. Greenough TC, Babcock GJ, Roberts A, Hernandez HJ, Thomas WD, Jr., Coccia JA et al. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. The Journal of Infectious Diseases. 2005; 191(4): 507-14.
76. Roberts A, Vogel L, Guarner J, Hayes N, Murphy B, Zaki S et al. Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters. Journal of Virology. 2005; 79(1): 503-11.
77. Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR et al. An efficient method to make human monoclonal antibodies from memory B cells: Potent neutralization of SARS coronavirus. Nature Medicine. 2004; 10(8): 871-5.
78. Rockx B, Feldmann F, Brining D, Gardner D, LaCasse R, Kercher L et al. Comparative pathogenesis of three human and zoonotic SARS-CoV strains in cynomolgus macaques. PloS One. 2011; 6(4): e18558.
79. Miyoshi-Akiyama T, Ishida I, Fukushi M, Yamaguchi K, Matsuoka Y, Ishihara T et al. Fully human monoclonal antibody directed to proteolytic cleavage site in severe acute respiratory syndrome (SARS) coronavirus S protein neutralizes the virus in a rhesus macaque SARS model. The Journal of Infectious Diseases. 2011; 203(11): 1574-81.
80. Kam YW, Kien F, Roberts A, Cheung YC, Lamirande EW, Vogel L et al. Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro. Vaccine. 2007; 25(4): 729-40.
81. Jaume M, Yip MS, Cheung CY, Leung HL, Li PH, Kien F et al. Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcgammaR pathway. Journal of Virology. 2011; 85(20): 10582-97.
82. Jaume M, Yip MS, Kam YW, Cheung CY, Kien F, Roberts A et al. SARS CoV subunit vaccine: Antibody-mediated neutralisation and enhancement. Hong Kong Medical Journal = Xianggang yi xue za zhi/Hong Kong Academy of Medicine. 2012; 18 Suppl 2: 31-6.
83. Tseng CT, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PloS One. 2012; 7(4): e35421.
84. Bolles M, Deming D, Long K, Agnihothram S, Whitmore A, Ferris M et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. Journal of Virology. 2011; 85(23): 12201-15.
85. Zheng BJ, Du LY, Zhao GY, Lin YP, Sui HY, Chan C et al. Studies of SARS virus vaccines. Hong Kong Medical Journal = Xianggang yi xue za zhi/Hong Kong Academy of Medicine. 2008; 14 Suppl 4: 39-43.
86. Tsunetsugu-Yokota Y. Large-scale preparation of UV-inactivated SARS coronavirus virions for vaccine antigen. Methods in Molecular Biology. 2008; 454: 119-26.
87. Du L, Zhang X, Liu J, Jiang S. Protocol for recombinant RBD-based SARS vaccines: protein preparation, animal vaccination and neutralization detection. Journal of Visualized Experiments: JoVE. 2011; (51).
88. Gai WW, Zhang Y, Zhou DH, Chen YQ, Yang JY, Yan HM. PIKA provides an adjuvant effect to induce strong mucosal and systemic humoral immunity against SARS-CoV. Virologica Sinica. 2011; 26(2): 81-94.
89. Milewska A, Ciejka J, Kaminski K, Karewicz A, Bielska D, Zeglen S et al. Novel polymeric inhibitors of HCoV-NL63. Antiviral Research. 2013; 97(2): 112-21.
90. Chang FR, Yen CT, Ei-Shazly M, Lin WH, Yen MH, Lin KH et al. Anti-human coronavirus (anti-HCoV) triterpenoids from the leaves of Euphorbia neriifolia. Natural Product Communications. 2012; 7(11): 1415-7.
91. Kim MK, Yu MS, Park HR, Kim KB, Lee C, Cho SY et al. 2, 6-Bis-arylmethyloxy-5-hydroxychromones with antiviral activity against both hepatitis C virus (HCV) and SARS-associated coronavirus (SCV). European Journal of Medicinal Chemistry. 2011; 46(11): 5698-704.
92. Li Q, Zhao Z, Zhou D, Chen Y, Hong W, Cao L et al. Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses. Peptides. 2011; 32(7): 1518-25.